United States Patent 6,753,445: Claim Scope, Lefamulin Coverage, Expiration, and Patent Landscape

U.S. Patent No. 6,753,445 covers a broad genus of 14-O-substituted mutilin antibiotics, including aminocyclohexyl sulfanyl acetyl derivatives associated with lefamulin. Its strongest protection was composition-of-matter coverage. The patent also includes salt, pharmaceutical-composition, antimicrobial-treatment, and veterinary-treatment claims. The patent is no longer an enforceable U.S. barrier to generic entry because its ordinary patent term has expired. Any current U.S. exclusivity for lefamulin must therefore arise from later patents, FDA regulatory exclusivity, or both.

What drug and chemical class does U.S. Patent 6,753,445 cover?

U.S. Patent 6,753,445 is directed to semisynthetic mutilin derivatives. Mutilins are pleuromutilin antibiotics that bind to the bacterial 50S ribosomal subunit and inhibit protein synthesis.

The claim set covers chemical modifications at the 14-position of the mutilin core. The principal structural motif is an acyl substituent linked through sulfur, oxygen, or related heteroatom-containing groups. The patent is particularly relevant to lefamulin, the active ingredient in XENLETA, because the claimed aminocyclohexyl sulfanyl acetyl derivatives encompass the lefamulin chemical series.

Lefamulin is a small-molecule antibiotic, not a biologic. Biosimilar pathways under the Biologics Price Competition and Innovation Act do not apply. A competing product would ordinarily proceed through an abbreviated new drug application, a 505(b)(2) application, or a full 505(b)(1) application, depending on the product and evidence package.

What does claim 1 protect?

Claim 1 covers four broad classes of 14-O-acylated mutilins:

14-O-[(cycloalkyl-sulfanyl)acetyl]mutilins;
14-O-[(cycloalkyl-alkyl-sulfanyl)acetyl]mutilins;
14-O-[(cycloalkoxy)acetyl]mutilins; and
14-O-[(cycloalkyl-alkoxy)acetyl]mutilins.

This is a Markush-style genus claim. It is not limited to one named compound, one cycloalkyl ring size, one stereoisomer, one salt, or one route of administration unless those restrictions appear elsewhere in the claim set or are imported through claim dependency.

The principal legal effect is breadth across multiple substituent classes. A compound may infringe claim 1 if it has:

a mutilin core;
substitution at the 14-oxygen position;
the claimed acetyl linkage; and
a cycloalkyl-containing sulfanyl or alkoxy substituent within one of the listed structural categories.

Claim 1 is potentially stronger against close chemical analogues than against distant pleuromutilin derivatives. A compound with a different attachment position, a materially different linker, or no covered cycloalkyl-sulfanyl or cycloalkoxy relationship would require separate infringement analysis.

How broad is claim 2?

Claim 2 covers compounds of formula I with extensive substituent variability. The listed variables permit variation in:

Variable	Permitted alternatives
R	Hydrogen
R1	Hydrogen or a substituted group containing sulfur, oxygen, or NR10
R10	Hydrogen or alkyl
R9	Amino, alkyl, aryl, or heterocyclyl; hydrogen is also permitted where X is oxygen
X	Sulfur, oxygen, or NR10
Y	Sulfur or oxygen
R2	Hydrogen or one or more substituents
R4 and R5	Hydrogen or alkyl
R3 and R3'	Hydrogen, deuterium, or halogen
R6, R7 and R8	Hydrogen or deuterium
m	0 to 4
n	0 to 10
p	0 to 10

The requirement that n plus p be at least one prevents the claim from covering compounds in which both relevant chain-length variables are zero.

Claim 2 is broader than the named-compound claims because it reaches a formula-defined genus. Its practical scope depends heavily on the patent specification, incorporated structural definitions, prosecution amendments, and any claim-construction rulings. The claim text alone does not establish whether all permutations were enabled or adequately described.

The claim also creates potential validity issues typical of broad chemical genus claims:

written-description support across all permitted substituent combinations;
enablement across the full numerical ranges for m, n, and p;
definiteness of formula boundaries;
consistency between the claim language and the drawings or chemical definitions; and
prior-art disclosure of related pleuromutilin derivatives.

What do claims 3 through 5 protect?

Claim 3: amino-acid derivatives

Claim 3 covers formula Ip compounds in which R1P is hydrogen or the residue of an amino acid. This language is directed to amino-acid-linked derivatives, which may include prodrug or salt-forming embodiments depending on the structure shown in formula Ip.

The claim is narrower than a general formula claim but may capture compounds designed to alter solubility, stability, absorption, or formulation characteristics.

Claims 4 and 5: aminocyclohexyl sulfanyl acetyl derivatives

Claim 4 identifies specific aminocyclohexyl compounds:

14-O-[(aminocyclohexan-2-yl-sulfanyl)acetyl]mutilin;
14-O-[(aminocyclohexan-3-yl-sulfanyl)acetyl]mutilin;
N-valyl aminocyclohexan-2-yl sulfanyl acetyl mutilin; and
N-valyl aminocyclohexan-3-yl sulfanyl acetyl mutilin.

Claim 5 identifies the corresponding 4-substituted cyclohexyl compounds:

14-O-[(aminocyclohexan-4-yl-sulfanyl)acetyl]mutilin; and
the corresponding N-valyl derivative.

These claims provide species-level protection beneath the broader genus claims. They are commercially important because the aminocyclohexyl sulfanyl acetyl series is associated with the lefamulin development program.

The exact scope depends on stereochemistry. For chiral cyclohexyl compounds, a claim to a particular stereoisomer may exclude the racemate or alternative diastereomer. The supplied text does not reproduce all stereochemical descriptors, so infringement analysis must use the issued patent text and chemical drawings rather than the abbreviated claim transcription.

What do claims 6 through 9 protect?

Claim	Subject matter	Commercial relevance
6	Salt of a claim 1 compound	Covers selected pharmaceutical salt forms, but only to the extent claim dependency is maintained
7	Pharmaceutical composition containing a claim 1 compound and carrier or diluent	Covers compositions using a claimed compound, but does not appear to require a particular dosage form, excipient, concentration, or release profile
8	Treatment of microbial diseases using a claim 1 compound	Method-of-use protection for antimicrobial treatment
9	Claim 8 where the subject is a non-human animal	Veterinary use

Claim 7 is not a modern formulation patent in the narrower commercial sense. It does not, on the supplied language, require a specific tablet, intravenous formulation, oral suspension, excipient system, particle size, polymorph, or manufacturing process.

Claim 8 is a broad method claim. It is not limited to one named organism, infection site, dose, route, or treatment duration unless those limitations appear in the issued claim or specification. Claim 9 separately preserves veterinary use, which can matter for animal-health products even when human treatment is the primary commercial application.

When did U.S. Patent 6,753,445 lose exclusivity?

The patent’s ordinary U.S. term has expired. The relevant date must be determined from the earliest effective priority and filing records, together with any patent-term adjustment, patent-term extension, terminal disclaimer, or other USPTO term record. The grant date alone does not control the expiration date. Under the modern patent-term regime, the baseline calculation is generally 20 years from the earliest effective nonprovisional or qualifying PCT filing date, not 20 years from grant (35 U.S.C. § 154).

As a result:

U.S. Patent 6,753,445 is not a current composition-of-matter barrier to an ANDA;
a new generic applicant would not ordinarily need to file a Paragraph IV certification against this expired patent;
the patent cannot support a new injunction against a product launched after expiration; and
any surviving relevance is historical, evidentiary, or related to patent-family analysis.

FDA regulatory exclusivity is separate from patent term. A new chemical entity may receive five years of FDA exclusivity, while a qualified infectious-disease product may receive additional regulatory benefits under the Generating Antibiotic Incentives Now framework. Those periods do not revive an expired patent. The FDA label and Orange Book must be reviewed independently from the USPTO record. (FDA, 2019; 21 U.S.C. § 355.)

What is the Orange Book status of this patent?

An expired composition patent is not a continuing Orange Book obstacle. The Orange Book may list later patents covering an approved drug, including patents directed to:

approved formulations;
dosage regimens;
methods of use;
crystalline or polymorphic forms;
pharmaceutical salts;
manufacturing processes; or
other approved-product characteristics.

U.S. Patent 6,753,445 should therefore be distinguished from any later patents listed for XENLETA or lefamulin. An Orange Book-listed patent can generate a Paragraph IV dispute only while it remains listed and legally relevant to the approved product. The presence of the 6,753,445 patent in historical patent databases does not establish that it remains listed or enforceable.

Which companies challenged this patent?

No current Paragraph IV challenge is directed to U.S. Patent 6,753,445 as an enforceable patent because the patent has expired. Any historical generic challenge would have had limited commercial value once the patent term ended.

The relevant competitive parties are:

Party type	Strategic issue
Lefamulin sponsor or licensee	Protection of later formulation, dosing, and regulatory exclusivity
Generic antibiotic manufacturers	ANDA development and invalidity or non-infringement positions against unexpired listed patents
505(b)(2) applicants	Potential reliance on published clinical data with differentiated formulation or indication
Other pleuromutilin developers	Design-around of the aminocyclohexyl sulfanyl acetyl scaffold
Veterinary pharmaceutical companies	Assessment of claim 9 and separate animal-health approvals

There is no biosimilar litigation pathway because lefamulin is a small molecule. Any current dispute would more likely involve later Orange Book patents, regulatory exclusivity, or trade-secret and manufacturing issues.

How strong is the patent estate for lefamulin?

The 6,753,445 patent was strongest as an early composition patent. Its strategic value came from the ability to cover the active chemical series before clinical development and regulatory approval.

Its present strength is limited by expiration. A current lefamulin patent estate would need to rely on later-filed rights, such as:

formulation patents for oral or intravenous dosage forms;
dosing-regimen patents;
polymorph, salt, or solid-state patents;
manufacturing and purification patents;
combination-treatment patents; and
patents directed to specific approved indications.

Composition patents filed after discovery can be commercially valuable, but they generally provide narrower protection than an early genus patent. Their enforceability also depends on whether a generic product necessarily practices the claimed formulation or method.

What generic launch risks remain?

A generic applicant faces different risks depending on the product design.

A conventional generic matching the approved lefamulin active ingredient would face:

any unexpired Orange Book patents;
FDA regulatory exclusivity;
bioequivalence requirements;
manufacturing control of the active pharmaceutical ingredient;
polymorph or salt-form requirements; and
potential infringement of formulation or method-of-use patents.

It would not face U.S. infringement liability based solely on expired Patent 6,753,445.

A non-infringing alternative could use a different salt, polymorph, formulation, or manufacturing route, but those changes do not eliminate regulatory requirements. A different chemical derivative may avoid claim 4 or 5 while still falling within a broader genus claim if the genus claim remains enforceable. Because the patent is expired, this distinction has primarily historical and freedom-to-operate value.

How does Patent 6,753,445 compare with other pleuromutilin patents?

Patent category	Typical subject matter	Relative scope
Early mutilin genus patent	Broad 14-O-substituted derivatives	Broadest chemical coverage
Species composition patent	One active compound or stereochemical series	Narrower but easier to map to a product
Retapamulin-related patent	Topical pleuromutilin derivatives and use	Different commercial product and indication
Lefamulin formulation patent	Oral or intravenous dosage form	Product-specific
Method-of-use patent	Pneumonia or other named infection	Limited to claimed indication and regimen
Manufacturing patent	Intermediate, crystallization, purification, or process	Process-dependent

Retapamulin, tiamulin, valnemulin, and lefamulin are all pleuromutilin-related antibiotics, but their patent estates should not be treated as interchangeable. Small changes in the 14-position substituent, stereochemistry, salt form, or formulation can determine whether a product falls within a particular claim.

Key Takeaways

U.S. Patent 6,753,445 is a composition-of-matter patent covering broad 14-O-substituted mutilin derivatives.
Claims 4 and 5 target aminocyclohexyl sulfanyl acetyl species associated with the lefamulin chemical series.
Claims 6 through 9 extend coverage to salts, pharmaceutical compositions, antimicrobial treatment, and veterinary use.
The patent is expired and does not create a current U.S. patent barrier to generic lefamulin entry.
No biosimilar pathway applies because lefamulin is a small molecule.
Current commercial protection must be evaluated through later patents, FDA exclusivity, Orange Book listings, and formulation or manufacturing rights.
The claim text alone is insufficient to resolve stereochemical scope, prosecution disclaimer, written-description validity, or overlap with later patents.

FAQs

Does U.S. Patent 6,753,445 claim lefamulin by name?

No. The patent uses structural genus and species claims rather than relying on the later INN name "lefamulin." The relevant question is whether the lefamulin structure falls within the issued chemical definitions.

Can an expired patent support a Paragraph IV certification?

No. Paragraph IV certifications address listed patents alleged to be invalid, unenforceable, or not infringed. An expired patent is not a continuing enforceable obstacle to approval or launch.

Are lefamulin salts protected by claim 6?

Claim 6 covers salts of compounds within claim 1. It does not automatically cover every salt of every pleuromutilin derivative described elsewhere in the patent. The dependency and structural relationship must be applied literally.

Does claim 7 cover every lefamulin formulation?

No. Claim 7 requires a pharmaceutical composition containing a claim 1 compound and a carrier or diluent. It may reach broad compositions, but it does not necessarily cover every formulation outside the claim’s dependency and structural limitations.

Can a generic avoid the patent by using a different pleuromutilin substituent?

Historically, potentially. A different substituent could avoid the specific species claims while still falling within claim 1 or claim 2. Because Patent 6,753,445 is expired, the issue now has limited U.S. launch significance but remains relevant to historical freedom-to-operate and patent-family analysis.

References

Food and Drug Administration. (2019). XENLETA (lefamulin) prescribing information. U.S. Department of Health and Human Services.
Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
U.S. Patent No. 6,753,445. (2004). Mutilin derivatives. United States Patent and Trademark Office.
United States Code. (2024). 35 U.S.C. § 154: Contents and term of patent; provisional rights.
United States Code. (2024). 21 U.S.C. § 355: New drugs.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0017031	Jul 11, 2000

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	029590	⤷ Start Trial
Austria	408596	⤷ Start Trial
Australia	2001276389	⤷ Start Trial
Australia	7638901	⤷ Start Trial
Brazil	0112452	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,753,445

Summary for Patent: 6,753,445